CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, ...

Acute respiratory syncytial virus was associated with elevated incidence of cardiovascular events among older adults, ...

CAMBRIDGE, MA / ACCESS Newswire / April 7, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present research across multiple infectious disease areas, including COVID-19, influ ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

While the ‘official’ flu season may still be a month or two away, reports indicate a rise in respiratory illnesses like the ...

India reported its last human H5N1 infection in 2021, a fatal case in an 11-year-old boy who had an underlying medical condition. However, in May 2024, Australia reported an H5N1 infection in an ...

The authors assessed the patient characteristics associated with RSV vaccination among older adults hospitalized during the ...

Pfizer Inc. has announced that the European Commission (EC) has issued a decision amending the marketing authorization for ...

Pfizer’s RSV vaccine Abrysvo receives European approval to help protect adults aged 18-59 against RSV lower respiratory tract disease: New York Wednesday, April 2, 2025, 09:00 H ...

Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to prevent RSV-associated lower respiratory tract disease (LRTD) in individuals aged 18 to 59 years ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...